Generally, in conventional advanced PEComas pathologically activated by the loss of the TSC1/TSC2 tumor suppressor complex, mTOR1 is a rational mechanistic target for the therapy with its inhibitors, such as rapamycin or everolimus [13]. This evidence concerns the gene TSC2 and neoplasm with perivascular epithelioid cell differentiation.